[Studies on suppurative lesion and bone distribution of peroral antimicrobial agents (LAPC and TFLX) to experimental infected rabbits].
The models of infection in the rabbits mandible using Streptococcus milleri and Bacteroides fragilis by the method of Satoh-Heimdahl were prepared. A penicillic peroral antimicrobial agent, lenamipicillin (LAPC), and pyridone carboxylic acid peroral antimicrobial agent, tosufloxacin tosilate (TFLX), were administered to infected and healthy groups. Drug concentrations in the serum, pus, mandible, maxilla, humerus, sternum, costa, ilium, femur, tibia, liver, and kidney were determined by a biological method. The data were submitted to pharmacodynamic analysis and compared. The following results were obtained. The concentration of LAPC in the serum and various bone tissues was 1.2-6.4 times higher in the infected group than in the healthy group. The concentration of TFLX in the serum and bone tissues was 1.1-3.7 times higher in the infected group than in the healthy group. Moreover, concentrations in the liver 1.1-fold and 2.1-fold higher in the infectious group than in the healthy group in the LAPC and TFLX administration groups, respectively, and 1.1-fold and 1.3-fold higher in the kidney in the LAPC and TFLX groups, respectively. Both LAPC and TFLX diffused to the pus more satisfactorily than to the serum. The Cmax ratios of pus to infected serum were 1.48 and 1.81 for LAPC and TFLX, respectively, and the AUC ratios of pus to infected serum were 1.31 and 1.62 in LAPC and TFLX, respectively. These results indicated that both LAPC and TFLX are distributed satisfactorily to the local foci in the mandible, and that their systemic diffusion exerted immediate clinical effects.
Tanaka
M
M
Department of Oral and Maxillofacial Surgery I, Nippon Dental University School of Dentistry at Tokyo.
Satoh
T
T
D042462:4-Quinolones; D000667:Ampicillin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001442:Bacteroides Infections / Q000188:drug therapy*; D001441:Bacteroides fragilis; D001682:Biological Availability; D001842:Bone and Bones / Q000378:metabolism*; D024841:Fluoroquinolones; D008336:Mandibular Diseases / Q000188:drug therapy*; D009287:Naphthyridines / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011817:Rabbits; D013290:Streptococcal Infections / Q000188:drug therapy*; D013492:Suppuration
D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D000667:Ampicillin; C045384:lenampicillin; C055185:tosufloxacin